The US Multi-Society Task Force on Colorectal Cancer has issued 11 consensus recommendations to improve the diagnosis and management of serrated polyposis syndrome (SPS), a condition associated with increased colorectal cancer risk that is frequently underrecognized. The guidance was developed by representatives of the ACG, AGA, and ASGE and published in Gastroenterology, The American Journal of Gastroenterology, and Gastrointestinal Endoscopy. The task force recommends using the 2019 WHO diagnostic criteria and tracking the number, size, and location of serrated polyps across a patient’s lifetime. It emphasizes that all serrated polyp types count toward diagnosis, including hyperplastic polyps, sessile serrated lesions,…
Author: Abhay Panchal
Two studies from the European Polyp Surveillance (EPoS) project suggest that extending post-polypectomy colonoscopy surveillance intervals may be safe for selected patients with high-risk adenomas or serrated polyps. The findings, published in The New England Journal of Medicine, come from one of the largest randomized investigations of colorectal polyp surveillance, involving nearly 21,000 patients across eight European countries. In EPoS II, 10,799 patients with high-risk adenomas were randomized to surveillance colonoscopy at either three or five years. At five years, colorectal cancer incidence was similar between the groups: 0.77% in the five-year group versus 0.82% in the three-year group, meeting…
A new analysis published in eGastroenterology suggests that Helicobacter pylori infection may be associated with an increased risk of colorectal cancer (CRC), potentially accounting for up to 22% of cases globally. Researchers reviewed data from 43 studies and found that H. pylori exposure was associated with a 1.59-fold higher CRC risk. However, estimates fell to 11.9% when the analysis was restricted to 14 higher-quality population-based and cohort studies, highlighting substantial variation across studies. The potential burden was highest in the Western Pacific region, where an estimated 25% of CRC cases were linked to H. pylori exposure. Mongolia had the highest…
The Centers for Medicare & Medicaid Services (CMS) has finalized its 2027 Medicare Physician Fee Schedule, introducing lower baseline physician payments, tighter remote patient monitoring (RPM) requirements, and changes to value-based care programs. The final rule includes steeper payment reductions than initially proposed, with conversion factors declining 2.31% for clinicians not qualifying through advanced alternative payment models and 1.83% for qualifying participants. CMS will also reduce payment by 20% for the lower-cost service when an office visit and certain minor procedures are billed on the same day, including visits billed with modifier 25. Physician groups, including the Medical Group Management…
A study published in NEJM AI found that large language models (LLMs) recommended substantially more expensive care than treating physicians across 200 deidentified outpatient and emergency department cases. Researchers evaluated 24 AI systems, comparing their proposed diagnostic tests, specialist referrals, and new medications with physicians’ documented plans. Across 20 general-purpose AI systems, the average estimated cost of recommended care was $314 per visit, compared with $97 for physicians — a difference of 216,or3.2timesthephysician-recommendedcost.AIsystemsalsorecommendedmorediagnostictesting(105 additional per visit) and specialist referrals ($111 additional), as well as nearly twice as many new medications (1.14 versus 0.59 per visit). A notable finding was that…
What would gastroenterology look like if we redesigned it around what is possible today? Earlier this month, I gave the Claire Benenson Lecture at Weill Cornell Medicine’s GI Grand Rounds, exploring what it would take to shift from GI 1.0 to GI 2.0. It’s also the focus of my upcoming book with Dr. Charles Accurso. Can exponential technologies available today help us build intelligent pathways that stay connected to patients between visits and reduce gaps in care? Can they take on bureaucratic tasks and give doctors more time to do doctor work? Thank you to Weill Cornell Medicine for making the…
Surgery Partners, one of the largest U.S. operators of outpatient surgery centers and short-stay hospitals, will be taken private by HealthSpan Partners, an affiliate of nonprofit health system Bon Secours Mercy Health, in a deal valued at approximately $5.7 billion, including debt. Shareholders will receive $23.50 per share, representing a 49% premium to the company’s previous closing price. The transaction is expected to close in the first quarter of 2027. Bain Capital, which has been a minority investor since 2017 and owns 39% of Surgery Partners, will retain a significant ownership stake following the acquisition. The deal will substantially expand…
Pennsylvania has enacted House Bill 1123, expanding insurance coverage for colorectal cancer screening in line with the latest American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) guidelines. The law will eliminate cost-sharing for screening-eligible individuals covered by state-regulated health plans and Medicaid, potentially expanding no-cost access to screening for approximately 2 million Pennsylvanians. It takes effect December 21, 2026. The legislation is expected to improve access to noninvasive screening options, including Guardant Health’s Shield blood-based CRC test. Shield detects cancer-associated alterations in cell-free DNA and is intended for average-risk adults aged 45 and older. A positive result requires…
Genmab and Incyte have announced a clinical trial collaboration to evaluate a new combination treatment for patients with first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC). The planned Phase 1/2 study will combine Genmab’s investigational bispecific antibody petosemtamab, which targets EGFR and LGR5, with Incyte’s investigational KRAS G12D inhibitor INCB161734 and standard-of-care chemotherapy. The combination brings together two complementary approaches: targeting EGFR and LGR5 pathways involved in tumor growth and cancer stem-like cells, while directly inhibiting the KRAS G12D mutation. KRAS mutations occur in approximately 40% of colorectal cancers, with G12D being the most common KRAS variant, making it an important…
Wearable devices are gaining interest in gastroenterology as tools for monitoring disease activity between clinical visits, particularly in inflammatory bowel disease (IBD) and motility disorders. In one study of 400 adults with IBD, more than 40% reported current or previous wearable use, and nearly 90% believed these devices could provide useful health information. Research suggests that changes in heart rate variability (HRV) may precede IBD flares, with one study reporting that commercial wearables predicted flares up to seven weeks before clinically detectable disease. Other emerging technologies include biosensor patches that measure inflammatory markers such as TNF-alpha in sweat and devices…
